ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

APH Alliance Pharma Plc

36.75
0.15 (0.41%)
18 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Alliance Pharma Plc LSE:APH London Ordinary Share GB0031030819 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.15 0.41% 36.75 36.70 36.95 37.10 36.35 36.70 997,061 16:35:09
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 167.42M 936k 0.0017 215.88 198.24M

Alliance Pharma PLC Director's Dealing (3108P)

09/10/2019 11:14am

UK Regulatory


Alliance Pharma (LSE:APH)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Alliance Pharma Charts.

TIDMAPH

RNS Number : 3108P

Alliance Pharma PLC

09 October 2019

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

Director's Dealing

Alliance Pharma plc (AIM: APH), the international healthcare group, announces that it has received notice that on 7 October 2019, Peter Butterfield, Chief Executive Officer of Alliance, exercised unapproved share options over 3,137,546 ordinary shares of 1p each in the Company ("Ordinary Shares") under the Company's Share Option Plans. The average exercise price was 34.5 pence.

Following the exercise, on 7 October 2019, Mr Butterfield sold 2,791,546 Ordinary Shares at a price of 73.5 pence per share. Following these transactions, Mr Butterfield's total beneficial interest in the Group is 374,376 Ordinary Shares, representing approximately 0.07 per cent. of the Group's issued share capital.

The 3,137,546 Ordinary Shares will be admitted to trading pursuant to an existing block listing, and will rank pari passu with the existing Ordinary Shares in issue.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 
 1    Details of the person discharging managerial responsibilities/person 
       closely associated 
 a)   Name                        Peter Butterfield 
     --------------------------  ------------------------------------------------- 
 2    Reason for the notification 
     ----------------------------------------------------------------------------- 
 a)   Position/status             Chief Executive Officer 
     --------------------------  ------------------------------------------------- 
 b)   Initial notification        Initial Notification 
       /Amendment 
     --------------------------  ------------------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ----------------------------------------------------------------------------- 
 a)   Name                        ALLIANCE PHARMA PLC 
     --------------------------  ------------------------------------------------- 
 b)   Legal Entity                213800RYIWZA4Q5WPZ13 
       Identifier 
     --------------------------  ------------------------------------------------- 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ----------------------------------------------------------------------------- 
 a)   Description of              Ordinary shares of 1 pence each 
       the financial 
       instrument, type 
       of instrument               GB0031030819 
 
       Identification 
       code 
     --------------------------  ------------------------------------------------- 
 b)   Nature of the                    a) Exercise of options 
       transaction                      b) Sale of Ordinary Shares 
     --------------------------  ------------------------------------------------- 
 c)   Currency                    GBP 
     --------------------------  ------------------------------------------------- 
 d)   Price(s) and                Price(s)                         Volume(s) 
       volume(s) 
     --------------------------  -------------------------------  ---------------- 
                                             a) 34.5 pence         a) 3,137,546 
                                              b) 73.5 pence         b) 2,791,546 
     --------------------------  -------------------------------  ---------------- 
 
 e)   Aggregated information      a) 3,137,546 Ordinary Shares, weighted average 
       - Aggregated                exercise price of 34.5 pence per Ordinary 
       volume                      Share. 
       - Price                     b) 2,791,546 Ordinary Shares, sold at a price 
       - Aggregated                of 73.5 pence per Ordinary Share, totalling 
       total                       GBP2,051,786.31. 
     --------------------------  ------------------------------------------------- 
 f)   Date of the transaction     7 October 2019 
     --------------------------  ------------------------------------------------- 
 g)   Place of the                London Stock Exchange, AIM 
       transaction 
     --------------------------  ------------------------------------------------- 
 

For further information:

   Alliance Pharma plc                                                           + 44 (0)1249 466966 

Peter Butterfield, Chief Executive Officer

Andrew Franklin, Chief Financial Officer

www.alliancepharma.co.uk

Buchanan + 44 (0)20 7466 5000

Mark Court / Sophie Wills / Hannah Ratcliff

   Numis Securities Limited                                                 + 44 (0)20 7260 1000 

Nominated Adviser: Freddie Barnfield

Corporate Broking: James Black

 
 Investec Bank plc                    + 44 (0) 20 7597 5970 
 Corporate Finance: Daniel Adams / 
  Ed Thomas 
 Corporate Broking: Patrick Robb / 
  Tejas Padalkar 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHMMMGGGLGGLZM

(END) Dow Jones Newswires

October 09, 2019 06:14 ET (10:14 GMT)

1 Year Alliance Pharma Chart

1 Year Alliance Pharma Chart

1 Month Alliance Pharma Chart

1 Month Alliance Pharma Chart

Your Recent History

Delayed Upgrade Clock